No full text
Article (Scientific journals)
Anti-laminin receptor antibody targeting of liposomes with encapsulated doxorubicin to human breast cancer cells in vitro.
Rahman, A.; Panneerselvam, M.; Guirguis, R. et al.
1989In Journal of the National Cancer Institute, 81 (23), p. 1794-800
Peer Reviewed verified by ORBi
 

Files


Full Text
No document available.

Send to



Details



Keywords :
Antibodies, Monoclonal/metabolism; Breast Neoplasms/drug therapy/immunology; Doxorubicin/administration & dosage; Drug Carriers; Humans; Laminin/immunology; Liposomes; Receptors, Immunologic/immunology/metabolism; Receptors, Laminin; Tumor Cells, Cultured
Abstract :
[en] The tumor cell laminin receptor is a cell-surface protein that binds laminin with high affinity (Kd = 1.0 nM). The putative ligand-binding domain of the laminin receptor has been molecularly cloned and sequenced. In the present study, we used the predicted amino acid sequence of the laminin receptor to generate synthetic peptide antigens and produced immunoglobulin M (IgM) anti-laminin receptor monoclonal antibodies. The disulfide bond group of the IgM molecule was used to couple the antibodies to the surface of liposomes encapsulating doxorubicin. The anti-laminin receptor monoclonal antibodies coupled to the liposomes bound avidly to the surface of MDA-MB-435S (MDA-435) human breast carcinoma cells, which have high numbers of laminin receptors. These antibody-coupled liposomes exhibited a low degree of binding to Hs 578Bst (Hs 578) normal human breast epithelial cells, which express a low number of laminin receptors. Excess liposomes competed for the binding of unbound laminin to the tumor cell surface, and excess laminin competed for binding with the liposomes. Antibody-coupled liposomes encapsulating doxorubicin were specifically more efficient in inhibiting colony formation by MDA-435 cells in vitro than unbound doxorubicin or liposomes without anti-laminin receptor monoclonal antibodies. Unbound doxorubicin inhibited thymidine uptake by 10%-20% in both Hs 578 and MDA-435 cells, whereas the antibody-coupled liposomes encapsulating doxorubicin inhibited thymidine uptake by 90% in MDA-435 cells but only 15% in Hs 578 cells. Thus, use of anti-laminin receptor monoclonal antibodies coupled with liposomes encapsulating doxorubicin represents a new strategy for selective targeting of doxorubicin to carcinoma cells with exposed laminin receptors.
Disciplines :
Oncology
Biochemistry, biophysics & molecular biology
Author, co-author :
Rahman, A.
Panneerselvam, M.
Guirguis, R.
Castronovo, Vincenzo ;  Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie générale et cellulaire - GIGA-R : Labo de recherche sur les métastases
Sobel, M. E.
Abraham, K.
Daddona, P. E.
Liotta, L. A.
Language :
English
Title :
Anti-laminin receptor antibody targeting of liposomes with encapsulated doxorubicin to human breast cancer cells in vitro.
Publication date :
1989
Journal title :
Journal of the National Cancer Institute
ISSN :
0027-8874
eISSN :
1460-2105
Publisher :
Oxford University Press, Cary, United States - North Carolina
Volume :
81
Issue :
23
Pages :
1794-800
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 25 May 2010

Statistics


Number of views
47 (1 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
19
Scopus citations®
without self-citations
17
OpenCitations
 
15

Bibliography


Similar publications



Contact ORBi